Date: 2016-05-17
Type of information: Opening of new premises
Compound: expansion of Devens biologics facility
Company: BMS (USA - NY)
Therapeutic area:
Type agreement: opening of new premises
Action mechanism:
Disease:
Details: * On May 17, 2016, BMS celebrated the completion of a major expansion at its Devens biologics facility designed to accelerate development of the company’s growing portfolio of biologics medicines. The $280 million project adds two new buildings to the 89-acre Devens campus: a Biologics Development Building for designing processes for the early production of investigational medicines, and a Clinical Manufacturing Building where investigational medicines will be produced to support clinical trials. Both are new capabilities for Devens, a site that had previously focused solely on large-scale, bulk biologics manufacturing. The expansion increases the site’s workforce, with approximately 200 new jobs having been added at the project’s initial completion rising to approximately 350 jobs over time. The two new buildings also add approximately 200,000 square feet to a site now comprised of eight major buildings in a 600,000 square-foot complex. Furthermore, the buildings add to the major investment the company has made at Devens, a former military base. When combined with the company’s initial $750 million investment to build the facility, the expansion project brings the company’s total investment at the site to more than $1 billion.
Financial terms:
Latest news:
